Back to Search
Start Over
The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study
- Source :
- BMC Research Notes
- Publication Year :
- 2015
-
Abstract
- Background The aim of this study is to investigate the prognostic relevance of the best objective response of metastatic target lesions during sunitinib treatment in patients with metastatic renal cell carcinoma. Methods Radiographic analysis of the best objective response according to the Response Evaluation Criteria in Solid Tumors was assessed in 50 patients. Clinicopathological characteristics including the Heng risk classification and sunitinib-related adverse reactions were compared among four patient subgroups [complete response or partial response (CR/PR), stable disease (SD), progressive disease (PD), and those without treatment evaluation (NE)]. Kaplan–Meier and Cox proportional regression analyses of progression-free survival and overall survival were performed to identify prognostic variables. Results The best objective response was CR/PR in 12 (24 %) patients, SD in 22 (44 %), PD in 6 (12 %), and NE in 10 (20 %). The incidence of hypertension and hypothyroidism was associated with a better objective response. Progression-free survival was 15.0, 9.2, 6.8, and 2.2 months in the CR/PR, SD, PD, and NE groups, respectively (P = 0.0004, log-rank test), while the corresponding median overall survival was 59.7, 24.2, 17.1, and 18.1 months, respectively (P = 0.007). Multivariate analysis revealed that hazard ratios for risk of death of the SD, PD, and NE groups were 4.51 (P = 0.06), 7.93 (P = 0.02), and 4.88 (P = 0.04), respectively, as compared to the CR/PR group. Conclusions Our findings suggested that the best objective response of target lesions was a prognostic marker for both progression-free survival and overall survival in sunitinib treatment. Furthermore, the incidence of sunitinib-induced hypertension was associated with a longer progression-free survival.
- Subjects :
- 0301 basic medicine
Oncology
Male
medicine.medical_specialty
Prognostic variable
Indoles
Survival
Kaplan-Meier Estimate
General Biochemistry, Genetics and Molecular Biology
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Japan
Renal cell carcinoma
Internal medicine
Carcinoma
Sunitinib
Medicine
Humans
Pyrroles
Carcinoma, Renal Cell
Aged
Demography
Proportional Hazards Models
Retrospective Studies
Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)
business.industry
Proportional hazards model
Incidence
Hazard ratio
General Medicine
Middle Aged
medicine.disease
030104 developmental biology
Treatment Outcome
RECIST
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Hypertension
Multivariate Analysis
Female
business
Progressive disease
medicine.drug
Research Article
Subjects
Details
- ISSN :
- 17560500
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- BMC research notes
- Accession number :
- edsair.doi.dedup.....0fc5c38c32850b16e406990c86179327